Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer's Disease.

ABSTRACT:

Background

Alzheimer's disease (AD) is a neurodegenerative disorder lacking any curative treatment up to now. Indeed, actual medication given to the patients alleviates only symptoms. The cytosolic phospholipase A2 (cPLA₂-IVA) appears as a pivotal player situated at the center of pathological pathways leading to AD and its inhibition could be a promising therapeutic approach.

Objective

A cPLA₂-IVA inhibiting peptide was identified in the present work, aiming to develop an original therapeutic strategy.

Methods

We targeted the cPLA₂-IVA using the phage display technology. The hit peptide PLP25 was first validated in vitro (arachidonic acid dosage [AA], cPLA₂-IVA cellular translocation) before being tested in vivo

SUBMITTER: Andre S 

PROVIDER: S-EPMC10789292 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature